ÂÜÀòÂÒÂ×

Rachael A Hagan has a diverse work experience in various roles and industries. Rachael A is currently the President and CEO of NephroDI Therapeutics, Inc. since July 2017. Rachael A also serves as a member of the External Review Board at the Midwest Biomedical Accelerator Consortium starting from January 2020. Rachael has been a part of the Executive Oversight Committee at the University of Calgary Early Cancer Detection Initiative (ECDI) since November 2017. Prior to that, they worked as a Consultant in Pitch Coach and Business Development Advisor. Rachael A also worked as a Business Development Adviser at BioComX - C3i starting from October 2014. Rachael served on the Business Advisory Board of ZEPHYRx LLC, a company that develops video games for respiratory therapy from May 2019 to August 2020. Rachael A was the Senior Director at EMORY UNIVERSITY / GEÂÜÀòÂÒÂ×IA INSTITUTE OF TECHNOLOGY, where they managed the Coulter Translational Partnership Fund from December 2013 to July 2017. Rachael also has experience as a Business Development professional at OtoNexus Medical Technologies Inc. from June 2013 to June 2015. Prior to that, they worked as a Senior Lecture at the University of Washington School of Pharmacy in 2013. Rachael A'searlier role as the Director at the University of Washington involved managing the Wallace H. Coulter Translational Partnership Fund, where they facilitated the development of commercially viable medical technologies.

Rachael A Hagan has a diverse education history. Rachael A first attended the University of South Alabama from 1983 to 1989, where they obtained a Bachelor of Arts (B.A.) degree in Criminology. Following this, they pursued further studies at Kieser College from 1997 to 2000, earning an Associate of Science (AS) degree in Computer Programming. Finally, from 2011 to 2013, Rachael A Hagan attended the University of Washington, where they completed a Master of Science (MS) degree in Regulatory Affairs - Pharmacy.